Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Dec 16, 2022 5:46pm
195 Views
Post# 35176991

A Different Deal

A Different DealTell Deborah that you want a different deal.

SInce they're going to sell the xB3 platform anyway, tell her to spin half of the platform out into another company and that it must be done before a vote on a deal can be held.

Tell her to issue shares in the new company to only current Bioasis shareholders of record, fully diluted, if they pay to exercise their options and warrants. The warrants should rep[riced to reflect the current disaster..

Then let the acquisition of Bioasis take place with the half ownership of the xB3 platform and the other half with the Bioasis shareholders. The Bioasis xB3 Platform Company shareholders will not be selling their shares in their new company.

Then Biodex can sell their half of the xB3 platform. The price is to be set by Biodexa and the new Bioasis shareholder xb3 platform holding company.

That way the sharks including DrDR get their piece, Biodexa gets some coin and the Bioasis shareholders participate on an equal footing with the interlopers.

The Bioasis shareholders get to choose their own executives in the xB3 holding company.

There need to be other details handled but it's a good start. And the current Bioasis/Midatech terms remain unchanged.except a couple of minor things. The Bioasis shareholdes get an undilutable 10% of Biodexa and a seat on the Biodexa BoD. 

And maybe Rathjen should not have a seat on the Biodexa BoD. Conflict of interest and all that.

jd
<< Previous
Bullboard Posts
Next >>